CN109153720B - 使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断 - Google Patents

使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断 Download PDF

Info

Publication number
CN109153720B
CN109153720B CN201780024373.4A CN201780024373A CN109153720B CN 109153720 B CN109153720 B CN 109153720B CN 201780024373 A CN201780024373 A CN 201780024373A CN 109153720 B CN109153720 B CN 109153720B
Authority
CN
China
Prior art keywords
clever
macrophages
gly
cys
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780024373.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109153720A (zh
Inventor
M-L.霍门
M.维塔拉
M.雅克恩
M.马克西莫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of CN109153720A publication Critical patent/CN109153720A/zh
Application granted granted Critical
Publication of CN109153720B publication Critical patent/CN109153720B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201780024373.4A 2016-04-18 2017-04-18 使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断 Active CN109153720B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20165336 2016-04-18
FI20165336 2016-04-18
PCT/FI2017/050286 WO2017182706A1 (en) 2016-04-18 2017-04-18 Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents

Publications (2)

Publication Number Publication Date
CN109153720A CN109153720A (zh) 2019-01-04
CN109153720B true CN109153720B (zh) 2022-10-21

Family

ID=58692521

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780024373.4A Active CN109153720B (zh) 2016-04-18 2017-04-18 使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断

Country Status (10)

Country Link
US (1) US10884000B2 (enExample)
EP (1) EP3445786B1 (enExample)
JP (2) JP7100588B2 (enExample)
KR (1) KR102403660B1 (enExample)
CN (1) CN109153720B (enExample)
AU (1) AU2017252344B2 (enExample)
BR (1) BR112018070350A2 (enExample)
CA (1) CA3020418A1 (enExample)
EA (1) EA201892313A1 (enExample)
WO (1) WO2017182706A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113895A1 (en) 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
US20220404366A1 (en) * 2019-11-11 2022-12-22 Faron Pharmaceuticals Oy Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment
CA3174858A1 (en) * 2020-04-20 2021-10-28 Juho JALKANEN Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
WO2023105118A1 (en) * 2021-12-07 2023-06-15 Faron Pharmaceuticals Oy Method for using inflammatory markers to guide anti-clever-1 cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057130A2 (en) * 2002-01-09 2003-07-17 Sirpa Jalkanen Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
WO2010122217A1 (en) * 2009-04-22 2010-10-28 Faron Pharmaceuticals Oy A novel cell and therapeutical and diagnostical methods based thereon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936983A (zh) 2012-11-09 2015-09-23 特朗斯吉有限公司 对单核细胞或其前体分化的调节
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057130A2 (en) * 2002-01-09 2003-07-17 Sirpa Jalkanen Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
WO2010122217A1 (en) * 2009-04-22 2010-10-28 Faron Pharmaceuticals Oy A novel cell and therapeutical and diagnostical methods based thereon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLEVER-1 as an immune suppressive molecule;Palani, Senthil;《University of Turku》;20160318;1-72 *

Also Published As

Publication number Publication date
JP7100588B2 (ja) 2022-07-13
AU2017252344B2 (en) 2023-12-21
WO2017182706A1 (en) 2017-10-26
EP3445786B1 (en) 2023-10-04
US10884000B2 (en) 2021-01-05
KR102403660B1 (ko) 2022-05-30
JP7302049B2 (ja) 2023-07-03
US20190064180A1 (en) 2019-02-28
CN109153720A (zh) 2019-01-04
KR20180133854A (ko) 2018-12-17
JP2019521312A (ja) 2019-07-25
AU2017252344A1 (en) 2018-10-11
EA201892313A1 (ru) 2019-03-29
CA3020418A1 (en) 2017-10-26
BR112018070350A2 (pt) 2019-01-29
EP3445786C0 (en) 2023-10-04
JP2022065088A (ja) 2022-04-26
EP3445786A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
JP7302049B2 (ja) Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断
JP4422903B2 (ja) 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
JP2021191765A (ja) Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用
CN112567026B (zh) Il-31改善用于癌症的基于巨噬细胞的过继性细胞疗法的功效
JP2002504334A (ja) Ｏｘ−４０レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
CN109810995B (zh) 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
TWI847958B (zh) 用精胺酸耗盡劑進行之組合癌症免疫療法
CN109311983B (zh) 人源化抗clever-1抗体及其用途
CN112955161B (zh) 通过活化细胞修复组织
KR20180095037A (ko) 수용성 종양괴사인자의 억제에 의한 암의 예방 및 치료
JP4987698B2 (ja) 癌関連抗原アナログペプチド、およびその利用
KR20180119605A (ko) ＨＬＡ-Ｂ５７ 개방 이형태체(open conformer)
CN114920841B (zh) 抗cd87抗体及其特异性嵌合抗原受体
CN102898508B (zh) 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
WO2018224614A1 (en) Vegf inhibitors for use for preventing and/or treating acne
HK1261998B (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents
CN108834402A (zh) 产生肿瘤浸润t细胞群的方法
HK1261998A1 (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents
JP2001508764A (ja) 免疫原性ｔｌｐ組成物
EP1367393A1 (en) Methods for using the CD 163 pathway for modulating an immune response
CN101230339B (zh) 大蹼铃蟾非晶状体βγ-晶状体蛋白与三叶因子蛋白复合物和基因及制法及用途
BG66049B1 (bg) Средство за конкурентно инхибиране и/или блокиране на карциноембрионалния антиген /сеа/

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261998

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant